Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AARP Rx Watchdog Report

Executive Summary

AARP's latest drug price study, issued Nov. 2, found prices rose 6.1% for nearly 200 of the most common brand name prescriptions during the 12 month period ending in June. The rate is slightly less than the 7.1% increase reported by AARP in 2004 (1"The Pink Sheet" April 18, 2005, p. 16). Products with the "sharpest" price increases over the first six months of 2005 included Sanofi-Aventis' Ambien 5 mg (14.4%) and Boehringer Ingelheim's Atrovent (18.6%). The Pharmaceutical Research & Manufacturers of America disputed the report, stating the Consumer Price Index price for prescription drugs increased only 3.4% for the same period...

You may also be interested in...



Price Increases For Branded Drugs Slower Since Medicare Drug Card – AARP

The prices pharmaceutical manufacturers charge wholesalers for brand name drugs have been increasing at a slower rate since the Medicare drug discount card became available, AARP concludes in an "Rx Watchdog Report" released April 12

Bristol/Exelixis Detail Survival Benefit For Opdivo/Cabometyx In Renal Cancer

Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.

Finance Watch: 2020 IPOs Surpass 2019 Total With 52 To Date

ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel